CMPS stays within ±12% of $13.37 through mid-October absent a company-specific Phase 3 readout or partnership announcement.

Predicted 2026-08-11 · Resolves 2026-10-15 · markets · Global

70%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

COMPASS Pathways is a company developing psilocybin-based treatments, and its stock (ticker: CMPS) currently trades around $13.37. The prediction is that the price will stay within about 12% of that level — so roughly between $11.77 and $14.97 — all the way to October 15, 2026. That's likely because no major news is expected: no big trial results, no major deals. Without a reason to buy or sell in a big way, the stock just drifts.

Resolution rule: YES if CMPS (NASDAQ) closing price on 2026-10-15 is within +/-12% of $13.37 (i.e. between $11.77 and $14.97), AND no COMPASS Pathways Phase 3 topline readout or partnership deal was announced in the interim. Check CMPS closing price on Nasdaq/Yahoo Finance and COMPASS IR press releases (compasspathways.com) on 2026-10-15.

Today's move is sub-2% on no catalyst. Nothing in the signals de-risks the asset; institutional capital stays sidelined until a dated event. Anchored to a specific ticker and price level observable daily.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →